[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659382":3},{"organization":4,"outcomesModule":7,"designInfo":37,"detailedDescription":40,"studyPopulation":41,"armGroups":42,"interventions":36,"overallOfficials":46,"centralContacts":50,"locations":57,"responsibleParty":143,"collaborators":36,"id":145,"slug":146,"hasResults":147,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":147,"sex":152,"minAge":153,"maxAge":36,"enrollmentInfo":154,"targetDuration":157,"studyType":158,"phases":36,"briefSummary":159,"conditions":160,"keywords":36,"overallStatus":163,"whyStopped":36,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},{"fullName":5,"class":6},"South Tees Hospitals NHS Foundation Trust","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":36},[9],{"measure":10,"description":11,"timeFrame":12},"Number of participants recruited","Recruitment of 200 participants with ≥75% of patients at medium or higher HFA-ICOS score","16 months",[14,18,20,23,25,28,31,33],{"measure":15,"description":16,"timeFrame":17},"Cardiac function","Cardiac function assessed by core lab artificial intelligence (AI) enabled echocardiogram via measurement of left ventricular ejection fraction (LVEF) in (%).","12 months",{"measure":15,"description":19,"timeFrame":17},"Cardiac function assessed by core lab artificial intelligence (AI) enabled echocardiogram via measurement of global longitudinal strain (GLS) in a negative percentage (%).",{"measure":21,"description":22,"timeFrame":17},"Cancer outcomes","Cancer outcomes - Entries recorded in the patient's medical records including cancer relapse\u002Frecurrence and diagnosis.",{"measure":21,"description":24,"timeFrame":17},"Cancer treatment completeness including number of cycles whether dosage was changed\u002Fdelayed\u002Freduced\u002Fdiscontinued - total dose of anthracycline received in (mg\u002Fm²) of body surface area.",{"measure":26,"description":27,"timeFrame":17},"Cardiovascular Outcomes","1Cardiovascular outcomes including cancer therapy related cardiac dysfunction (CTRCD). Entries as recorded in the patients' medical records including:\n\n* new diagnoses of heart failure\n* new diagnoses of atrial fibrillation\n* new diagnoses of myocardial infarction\n* new diagnoses of stroke or Transient Ischaemic Attack (TIA)\n* new diagnoses of deep vein thrombosis (DVT)\n* new diagnoses of Pulmonary Embolous (PE).",{"measure":29,"description":30,"timeFrame":17},"Quality of Life","Measurement of health-related quality of life of cancer patients through completion of EORTC-QLQ-C30 questionnaire.\n\nMost items use a 4-point scale ranging from 1 (\"Not at all\") to 4 (\"Very much\"); the global health\u002FQoL items towards the end of the questionnaire use a 7-point scale from 1 (\"Very poor\") to 7 (\"Excellent\").\n\nOverall scores are calculated by adding up the numerical response values in a section and calculating an average score. This score is then converted to a 0-100 score using the scoring manual.\n\nA higher score means a better level of functioning or higher quality of life, a lower score signifies lower QoL.",{"measure":29,"description":32,"timeFrame":17},"Measurement of patient-reported Quality of Life assessments through completion of the EQ-5D-5L questionnaire.",{"measure":34,"description":35,"timeFrame":17},"Biobanking and data collection","To facilitate translational research through the biobanking of clinical samples (including biomarkers and genomics)",null,{"allocation":36,"interventionModel":36,"interventionModelDescription":36,"primaryPurpose":36,"observationalModel":38,"timePerspective":39,"maskingInfo":36},"COHORT","PROSPECTIVE","The overarching rationale of BHF-COLLATE is to establish the first phase of a UK multicentre cardio-oncology registry platform focused on anthracycline chemotherapy. Phase I is primarily designed as a feasibility and infrastructure building registry to establish a functioning multidisciplinary research network, harmonised study procedures, core imaging and biobanking workflows, and scalable data collection processes capable of supporting future national registry expansion and interventional clinical trials.\n\nIn parallel, exploratory clinical, imaging and biomarker analyses will improve understanding of the cardiovascular consequences of anthracycline chemotherapy in real-world clinical practice and help inform the design of future translational and interventional cardio-oncology studies.\n\nThrough the establishment of this first phase, and recruitment of a multicentre UK anthracycline registry, the study aims to comprehensively phenotype patients receiving anthracycline chemotherapy in order to:\n\nestablish a collaborative research network and platform to support future interventional clinical trials in cardio-oncology facilitate translational research through the biobanking of clinical samples linked to detailed baseline clinical assessments, cardiac imaging, and longitudinal follow-up data generate mechanistic insights to inform the design of future clinical trials and the development of improved diagnostic, risk-stratification, and surveillance strategies.","Participants will be recruited from centres treating haemato-oncology and oncology patients and will be adult patients (18 years and above) who are due to receive anthracycline-based chemotherapy for their cancer\\* and provide written informed consent prior to study participation.\n\n\\*Participants are likely to be those being treated for breast cancer, lymphoma and sarcoma. Where patients need an expedited start to their anthracycline-based chemotherapy regimen for urgent clinical reasons that precludes enrolment prior to the start of cycle 1 (e.g. patients with NHL where treatment must start within a couple of days), they can still be included as long as consent, baseline assessments and eligibility is confirmed prior to the start of cycle 2.",[43],{"label":44,"type":36,"description":45,"interventionNames":36},"Anthracycline patients","Adult patients with confirmed solid organ or haematological malignancy; Adults aged 18 years or older; Planned to receive anthracycline chemotherapy; or prior to the start of the second cycle of anthracycline chemotherapy for those who required an urgent start to their chemotherapy for clinical reasons.",[47],{"name":48,"affiliation":5,"role":49},"David Austin","PRINCIPAL_INVESTIGATOR",[51],{"name":52,"role":53,"phone":54,"phoneExt":55,"email":56},"BHF COLLATE study team","CONTACT","01642 850 850","58441","stees.bhfcollate@nhs.net",[58,75,89,103,117,129],{"facility":59,"status":36,"city":60,"state":36,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"County Durham and Darlington NHS Foundation Trust","Darlington","DL3 6HX","United Kingdom","UK",{"type":65,"coordinates":66},"Point",[67,68],-1.55039,54.52429,{"lat":68,"lon":67},[71],{"name":72,"role":53,"phone":73,"phoneExt":36,"email":74},"Sophie Haney","01913332333","sophiehaney@nhs.net",{"facility":76,"status":36,"city":77,"state":36,"zip":78,"country":62,"countryCode":63,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Greater Glasgow and Clyde NHS Trust","Glasgow","G12 0XH",{"type":65,"coordinates":80},[81,82],-4.25763,55.86515,{"lat":82,"lon":81},[85],{"name":86,"role":53,"phone":87,"phoneExt":36,"email":88},"Matthew Wilson","01412014444","matthew.wilson@nhs.scot",{"facility":90,"status":36,"city":91,"state":36,"zip":92,"country":62,"countryCode":63,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Hull University Teaching Hospitals NHS Foundation Trust","Hull","HU3 2JZ",{"type":65,"coordinates":94},[95,96],-0.33525,53.7446,{"lat":96,"lon":95},[99],{"name":100,"role":53,"phone":101,"phoneExt":36,"email":102},"James Bailey","01482875875","james.bailey6@nhs.net",{"facility":104,"status":36,"city":105,"state":36,"zip":106,"country":62,"countryCode":63,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Barts Health NHS Trust","London","E1 2ES",{"type":65,"coordinates":108},[109,110],-0.12574,51.50853,{"lat":110,"lon":109},[113],{"name":114,"role":53,"phone":115,"phoneExt":36,"email":116},"Charlotte Manisty","02073777000","charlotte.manisty@nhs.net",{"facility":5,"status":36,"city":118,"state":36,"zip":119,"country":62,"countryCode":63,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Middlesbrough","TS43BW",{"type":65,"coordinates":121},[122,123],-1.23483,54.57623,{"lat":123,"lon":122},[126],{"name":48,"role":53,"phone":127,"phoneExt":36,"email":128},"01642850850","david.austin@nhs.net",{"facility":130,"status":36,"city":131,"state":36,"zip":132,"country":62,"countryCode":63,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Newcastle upon Tyne Hospitals NHS Foundation Trust","Newcastle","NE77DN",{"type":65,"coordinates":134},[135,136],-5.88979,54.21804,{"lat":136,"lon":135},[139],{"name":140,"role":53,"phone":141,"phoneExt":36,"email":142},"Christopher Plummer","01912336161","chris.plummer@nhs.net",{"type":144,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100659382","bhf-collate-uk-prospective-multi-centre-observational-cardio-oncology-anthracycline-registry-100659382",false,"NCT07864467","BHF-COLLATE: UK Prospective, Multi-centre, Observational, Cardio-oncology Anthracycline Registry","BHF-COLLATE","Inclusion Criteria:\n\n* Adult patients with confirmed solid organ or haematological malignancy;\n* Adults aged 18 years or older;\n* Planned to receive anthracycline chemotherapy; or prior to the start of the second cycle of anthracycline chemotherapy for those who required an urgent start to their chemotherapy for clinical reasons;\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Expected lifespan of under one year;\n* Not expected to complete the planned course of chemotherapy.","ALL","18 Years",{"count":155,"type":156},200,"ESTIMATED","12 Months","OBSERVATIONAL","The study aims to collect information on how cancer treatment affects heart health. This will include collecting baseline medical information, storing blood samples, recording cancer treatment, and analysing heart scans across about 200 patients in several UK hospitals. We are aiming to: collect health information and store blood samples, alongside heart scans, to learn more about heart health after chemotherapy; improve understanding of why some patients develop heart problems, so that better tests, monitoring, and treatments can be developed in the future; build a UK-wide research group.",[161,162],"Cancer and \u002F or Hematological Malignancy","Anthracycline-induced Cardiotoxicity","NOT_YET_RECRUITING","2026-10-02",{"date":166,"type":167},"2026-10-07","ACTUAL",{"date":169,"type":156},"2026-09-30",{"date":171,"type":156},"2029-11-30",{"name":5,"class":6},6]